Xencorincis A Biotechnology Company Based In Monroviacaliforniafounded In 1997 By Drbassil Dahiyat And Drstephen Mayoas A Spinout From Caltechxencor Has Played A Significant Role In The Los Angeles Biotech Industryfocusing On The Development Of Innovative Antibody Therapeutics The Company Utilizes Its Proprietary Xmab Protein Engineering Platform To Enhance The Performance Of Antibodiesthis Technology Enables The Creation Of Bispecific Antibodies And Other Novel Structures For Various Therapeutic Applicationsxencor Has A Diverse Portfolio Of Over 20 Therapeutic Antibody Programs In Clinical Developmentincluding Xmab5871Tavneos Which Is Approved For Treating Anca Associated Vasculitisand Plamotamabxmab13 A Bispecific Antibody For B Cell Lymphomas Xencor Has Formed Strategic Partnerships With Major Pharmaceutical Companiesincluding Amgen And Novartisto Advance Its Therapeutic Programsthe Company Reported A Total Revenue Of $618 8 Million In 2024Reflecting Its Growth And Successful Collaborations In The Biotechnology Sector
No conferences found for this company.
| Company Name | Xencor Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
